Developer docs
API playgroundTry for free, no card

Search company profiles

Novartis China

Full company profile

uuid003dmhl

Namestring
Novartis China
Legal namestring
Novartis AG
Websiteurl
novartis.com.cn
Company typeenum
Public
Founded yearint
1996
Descriptiontext

Novartis China is the China operations of Novartis AG, a publicly listed Swiss multinational pharmaceutical company headquartered in Basel, Switzerland (SIX Swiss Exchange: NOVN). The entity operates in China through four wholly-owned subsidiaries — Beijing Novartis Pharmaceutical Co., Ltd. (北京诺华制药有限公司), Novartis (China) Biomedical Research Co., Ltd. (诺华(中国)生物医学研究有限公司), Shanghai Novartis Trading Co., Ltd. (上海诺华贸易有限公司), and Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd. (诺华医药科技(浙江)有限公司) — covering pharmaceutical manufacturing, biomedical research, trading, and pharmaceutical technology respectively.

The company markets an extensive portfolio of innovative pharmaceuticals across oncology (Kisqali, Tabrecta, Pluvicto, Scemblix, Tibsovo, Piqray, Tafinlar+Mekinist), immunology (Cosentyx, Zhuole), neuroscience (Kesimpta, Wanlena), cardiovascular (Leqvio, Nuoxintuo), ophthalmology (Beovu, Xiidra), and rare diseases (FABhalia/Iptacopan for PNH, cGVHD, IgAN; Adakveo for sickle cell disease; Zolgensma for SMA; Revellan). The portfolio spans multiple technology modalities including small molecules, monoclonal antibodies, siRNA therapy (Leqvio), radioligand therapy (Pluvicto), gene therapy (Zolgensma), and complement pathway inhibition (FABhalia), reflecting direct transfer of the parent's advanced R&D pipeline into the China market.

Novartis China monetizes through pharmaceutical product sales distributed via a direct medical-representative field force covering hospitals and healthcare institutions nationwide, complemented by strategic retail partnerships, hospital and retail pharmacy channels, and dedicated product/adverse-event hotlines for original pharma and oncology. Pricing is not publicly disclosed; commercial economics in China for innovative drugs are shaped by inclusion in the National Reimbursement Drug List (NRDL) through government-mediated negotiations, which the company has actively pursued — securing inclusion of multiple innovative drugs in the 2025 NRDL. Customers are ultimately patients (via hospitals and retail pharmacies) across oncology, immunology, cardiovascular, and rare-disease therapeutic areas.

Short descriptiontext

Novartis China markets an innovative pharmaceutical portfolio spanning oncology, immunology, cardiovascular, neuroscience, ophthalmology, and rare diseases — including radioligand therapy, siRNA, and gene therapy — through four wholly-owned subsidiaries and a direct field force, with recent growth driven by multiple NMPA approvals and 2025 NRDL inclusions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
innovative pharmaceuticals, oncology medicines, rare disease therapies, cardiovascular drugs, biomedical research
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Innovative Pharmaceuticals
No data
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Novartis China develops, manufactures, and commercializes innovative pharmaceutical medicines across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, ophthalmology, and rare diseases. The company operates through wholly-owned subsidiaries handling pharmaceutical manufacturing, biomedical research, and trading, distributing products via medical representatives to hospitals and healthcare institutions across mainland China.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Novartis China operates as a diversified pharmaceutical company offering an extensive portfolio of innovative medicines and pipeline candidates across multiple therapeutic areas. The product portfolio includes: Cosentyx (Secukinumab) for immunology/dermatology; Kisqali (Ribociclib) and Piqray (Alpelisib) for oncology; Kesimpta (Ofatumumab) and Wanlena (Siponimod) for neuroscience/MS; Leqvio (Inclisiran) for cardiovascular disease; Tabrecta (Capmatinib) for lung cancer; FABhalia (Iptacopan) for rare diseases (PNH, cGVHD, IgAN); Beovu (Brolucizumab) for ophthalmology; Nuoxintuo (Sacubitril Valsartan) for heart failure; and Pluvicto (177Lu-PSMA-617) for radioligand therapy. The company also maintains a robust R&D pipeline and offers Sandoz generic antibiotics through its subsidiary. Products span both launched commercial medicines and investigational candidates in development.

Product and service20 records
1Cosentyx (Secukinumab)
CategoryImmunology / Dermatology Pharmaceutical
Description

IL-17A inhibitor for treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, pediatric arthritis, and enthesitis-associated arthritis; available as self-injection pen for patient convenience.

2Kisqali (Ribociclib)
CategoryOncology Pharmaceutical
Description

CDK4/6 inhibitor for HR+/HER2- breast cancer; first-line therapy for advanced breast cancer and adjuvant treatment for early breast cancer.

3Kesimpta (Ofatumumab)
CategoryNeuroscience Pharmaceutical
Description

B-cell targeted therapy for relapsing multiple sclerosis; first and only self-injectable B-cell therapy for MS patients, providing at-home treatment.

4Wanlena (Siponimod)
CategoryNeuroscience Pharmaceutical
Description

S1P receptor modulator for active secondary progressive multiple sclerosis (SPMS) and relapsing forms of MS.

5Leqvio (Inclisiran)
CategoryCardiovascular Pharmaceutical
Description

First siRNA therapy for cardiovascular disease; twice-yearly dosing for sustained LDL cholesterol lowering.

6Tabrecta (Capmatinib)
CategoryOncology Pharmaceutical
Description

MET inhibitor for advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations; precision medicine for molecularly selected patients.

7FABhalia (Iptacopan)
CategoryRare Disease Pharmaceutical
Description

First oral monotherapy for Paroxysmal Nocturnal Hemoglobinuria (PNH), chronic graft-versus-host disease, and IgA nephropathy (IgAN); complement pathway inhibitor.

8Beovu (Brolucizumab)
CategoryOphthalmology Pharmaceutical
Description

Anti-VEGF therapy for wet age-related macular degeneration (wAMD); up to 16 weeks between doses.

9Nuoxintuo (Sacubitril Valsartan)
CategoryCardiovascular Pharmaceutical
Description

ARNI (Angiotensin Receptor-Neprilysin Inhibitor) for chronic heart failure; won International Galen Awards Best Pharmaceutical Product.

10Zhuole (Omalizumab)
CategoryImmunology Pharmaceutical
Description

Anti-IgE therapy for chronic spontaneous urticaria and asthma; available as prefilled injection for home use.

11Pluvicto (177Lu-PSMA-617)
CategoryOncology Pharmaceutical
Description

Radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC); targeted radiation therapy using PSMA-binding molecule linked to lutetium-177.

12Scemblix (Asciminib)
CategoryOncology Pharmaceutical
Description

STAMP inhibitor for chronic myeloid leukemia (CML); treatment option for patients who have failed prior therapies.

13Tibsovo (Ivosidenib)
CategoryOncology Pharmaceutical
Description

IDH1 inhibitor for relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutation.

14Revellan (Eltrombopag)
CategoryRare Disease Pharmaceutical
Description

Thrombopoietin receptor agonist for chronic immune thrombocytopenia (ITP) in adults and children.

15Adakveo (Crizanlizumab)
CategoryRare Disease Pharmaceutical
Description

Anti-P-selectin antibody for vaso-occlusive crisis prevention in sickle cell disease.

16Zolgensma (Onasemnogene abeparvovec)
CategoryGene Therapy Pharmaceutical
Description

Gene therapy for spinal muscular atrophy (SMA); one-time intravenous treatment with potential lifetime benefit.

17Xiidra (Lifitegrast)
CategoryOphthalmology Pharmaceutical
Description

LFA-1 antagonist for treatment of dry eye disease; addresses ocular inflammation.

18Tafinlar (Dabrafenib) + Mekinist (Trametinib)
CategoryOncology Pharmaceutical
Description

BRAF/MEK inhibitor combination for BRAF V600 mutation-positive melanoma, NSCLC, and pediatric low-grade glioma.

19Piqray (Alpelisib)
CategoryOncology Pharmaceutical
Description

PI3K inhibitor for PIK3CA-mutated breast cancer; first targeted therapy for PIK3CA mutation.

20Sandoz Antibiotics Portfolio
CategoryGeneric Antibiotics Pharmaceutical
Description

Sandoz generic antibiotics including cephalosporins; essential medicines for infectious disease treatment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Roche China
TypeDirect peer
Description

Roche China is the China subsidiary of F. Hoffmann-La Roche, a direct multinational peer with overlapping oncology, ophthalmology, and immunology portfolios, including breast cancer and ophthalmology assets that compete directly with Novartis's Kisqali and Beovu.

2Eli Lilly China
TypeDirect peer
Description

Eli Lilly China competes with Novartis in oncology, immunology, and diabetes/obesity (cardiometabolic), with overlapping self-injection and self-administration platforms and similar NRDL negotiation dynamics.

TypeDirect peer
Description

Sanofi China is a direct peer in immunology, rare disease, and specialty care, operating comparable hospital sales, patient support, and NRDL inclusion processes for high-cost innovative biologics.

4Bristol-Myers Squibb China
TypeDirect peer
Description

Bristol-Myers Squibb China directly competes with Novartis in oncology (immuno-oncology vs. Kisqali/Tabrecta) and operates a similar NRDL-driven access model for innovative specialty drugs in mainland China.

TypeDirect peer
Description

AstraZeneca China is a leading multinational oncology and rare disease franchise with strong NRDL inclusion rates, competing with Novartis in lung cancer (Tabrecta), breast cancer, and specialty cardiovascular therapy.

TypeDirect peer
Description

AbbVie China directly competes with Novartis's immunology franchise (Cosentyx vs. Humira/Skyrizi/Rinvoq) and operates similar specialty biologic reimbursement and NRDL access strategy in mainland China.

7Merck & Co. (MSD) China
TypeDirect peer
Description

MSD China competes directly with Novartis in oncology (Keytruda versus Kisqali/Tabrecta) and runs a parallel NRDL negotiation and hospital sales infrastructure, making it a near-comparable multinational peer in oncology access strategy.

TypeDirect peer
Description

GSK China competes in specialty pharmaceuticals and vaccines in China with parallel hospital sales models and NRDL negotiation dynamics, making it a relevant multinational peer for portfolio and channel comparison.

TypeDirect peer
Description

Bayer China competes with Novartis's cardiovascular franchise (Leqvio, Nuoxintuo) and oncology offerings, operating comparable hospital-focused sales and NRDL inclusion processes for innovative chronic disease drugs.

TypeDirect peer
Description

Pfizer China operates a similarly diversified innovative pharmaceutical franchise across oncology, rare disease, and immunology in mainland China, making it a comparable multinational peer for portfolio breadth, hospital channel coverage, and NRDL strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novartis China

Innovative Pharmaceuticalsnovartis.com.cn

Novartis China markets an innovative pharmaceutical portfolio spanning oncology, immunology, cardiovascular, neuroscience, ophthalmology, and rare diseases — including radioligand therapy, siRNA, and gene therapy — through four wholly-owned subsidiaries and a direct field force, with recent growth driven by multiple NMPA approvals and 2025 NRDL inclusions.

What Novartis China does

Novartis China is the China operations of Novartis AG, a publicly listed Swiss multinational pharmaceutical company headquartered in Basel, Switzerland (SIX Swiss Exchange: NOVN). The entity operates in China through four wholly-owned subsidiaries — Beijing Novartis Pharmaceutical Co., Ltd. (北京诺华制药有限公司), Novartis (China) Biomedical Research Co., Ltd. (诺华(中国)生物医学研究有限公司), Shanghai Novartis Trading Co., Ltd. (上海诺华贸易有限公司), and Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd. (诺华医药科技(浙江)有限公司) — covering pharmaceutical manufacturing, biomedical research, trading, and pharmaceutical technology respectively.

The company markets an extensive portfolio of innovative pharmaceuticals across oncology (Kisqali, Tabrecta, Pluvicto, Scemblix, Tibsovo, Piqray, Tafinlar+Mekinist), immunology (Cosentyx, Zhuole), neuroscience (Kesimpta, Wanlena), cardiovascular (Leqvio, Nuoxintuo), ophthalmology (Beovu, Xiidra), and rare diseases (FABhalia/Iptacopan for PNH, cGVHD, IgAN; Adakveo for sickle cell disease; Zolgensma for SMA; Revellan). The portfolio spans multiple technology modalities including small molecules, monoclonal antibodies, siRNA therapy (Leqvio), radioligand therapy (Pluvicto), gene therapy (Zolgensma), and complement pathway inhibition (FABhalia), reflecting direct transfer of the parent's advanced R&D pipeline into the China market.

Novartis China monetizes through pharmaceutical product sales distributed via a direct medical-representative field force covering hospitals and healthcare institutions nationwide, complemented by strategic retail partnerships, hospital and retail pharmacy channels, and dedicated product/adverse-event hotlines for original pharma and oncology. Pricing is not publicly disclosed; commercial economics in China for innovative drugs are shaped by inclusion in the National Reimbursement Drug List (NRDL) through government-mediated negotiations, which the company has actively pursued — securing inclusion of multiple innovative drugs in the 2025 NRDL. Customers are ultimately patients (via hospitals and retail pharmacies) across oncology, immunology, cardiovascular, and rare-disease therapeutic areas.

Novartis China firmographics

Firmographics
Name
Novartis China
Legal name
Novartis AG
Website
https://novartis.com.cn
Company type
Public
Founded year
1996
Operating status
Operating
Headcount range
251–500 employees
Short description
Novartis China markets an innovative pharmaceutical portfolio spanning oncology, immunology, cardiovascular, neuroscience, ophthalmology, and rare diseases — including radioligand therapy, siRNA, and gene therapy — through four wholly-owned subsidiaries and a direct field force, with recent growth driven by multiple NMPA approvals and 2025 NRDL inclusions.
Ownership category
akta.pro rank

Novartis China industry classification

Industry
Product category
Innovative Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Innovative pharmaceuticals
  • Oncology medicines
  • Rare disease therapies
  • Cardiovascular drugs
  • Biomedical research

Where Novartis China is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Markets served

Novartis China business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Distribution channels3 records

Marketing channels3 records

Novartis China product offering

Product offering

Core offering

Novartis China develops, manufactures, and commercializes innovative pharmaceutical medicines across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, ophthalmology, and rare diseases. The company operates through wholly-owned subsidiaries handling pharmaceutical manufacturing, biomedical research, and trading, distributing products via medical representatives to hospitals and healthcare institutions across mainland China.

Product overview

Novartis China operates as a diversified pharmaceutical company offering an extensive portfolio of innovative medicines and pipeline candidates across multiple therapeutic areas. The product portfolio includes: Cosentyx (Secukinumab) for immunology/dermatology; Kisqali (Ribociclib) and Piqray (Alpelisib) for oncology; Kesimpta (Ofatumumab) and Wanlena (Siponimod) for neuroscience/MS; Leqvio (Inclisiran) for cardiovascular disease; Tabrecta (Capmatinib) for lung cancer; FABhalia (Iptacopan) for rare diseases (PNH, cGVHD, IgAN); Beovu (Brolucizumab) for ophthalmology; Nuoxintuo (Sacubitril Valsartan) for heart failure; and Pluvicto (177Lu-PSMA-617) for radioligand therapy. The company also maintains a robust R&D pipeline and offers Sandoz generic antibiotics through its subsidiary. Products span both launched commercial medicines and investigational candidates in development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cosentyx (Secukinumab) IL-17A inhibitor for treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis, pediatric arthritis, and enthesitis-associated arthritis; available as self-injection pen for patient convenience.
  • Kisqali (Ribociclib) CDK4/6 inhibitor for HR+/HER2- breast cancer; first-line therapy for advanced breast cancer and adjuvant treatment for early breast cancer.
  • Kesimpta (Ofatumumab) B-cell targeted therapy for relapsing multiple sclerosis; first and only self-injectable B-cell therapy for MS patients, providing at-home treatment.
  • Wanlena (Siponimod) S1P receptor modulator for active secondary progressive multiple sclerosis (SPMS) and relapsing forms of MS.
  • Leqvio (Inclisiran) First siRNA therapy for cardiovascular disease; twice-yearly dosing for sustained LDL cholesterol lowering.
  • Tabrecta (Capmatinib) MET inhibitor for advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations; precision medicine for molecularly selected patients.
  • FABhalia (Iptacopan) First oral monotherapy for Paroxysmal Nocturnal Hemoglobinuria (PNH), chronic graft-versus-host disease, and IgA nephropathy (IgAN); complement pathway inhibitor.
  • Beovu (Brolucizumab) Anti-VEGF therapy for wet age-related macular degeneration (wAMD); up to 16 weeks between doses.
  • Nuoxintuo (Sacubitril Valsartan) ARNI (Angiotensin Receptor-Neprilysin Inhibitor) for chronic heart failure; won International Galen Awards Best Pharmaceutical Product.
  • Zhuole (Omalizumab) Anti-IgE therapy for chronic spontaneous urticaria and asthma; available as prefilled injection for home use.
  • Pluvicto (177Lu-PSMA-617) Radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC); targeted radiation therapy using PSMA-binding molecule linked to lutetium-177.
  • Scemblix (Asciminib) STAMP inhibitor for chronic myeloid leukemia (CML); treatment option for patients who have failed prior therapies.
  • Tibsovo (Ivosidenib) IDH1 inhibitor for relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutation.
  • Revellan (Eltrombopag) Thrombopoietin receptor agonist for chronic immune thrombocytopenia (ITP) in adults and children.
  • Adakveo (Crizanlizumab) Anti-P-selectin antibody for vaso-occlusive crisis prevention in sickle cell disease.
  • Zolgensma (Onasemnogene abeparvovec) Gene therapy for spinal muscular atrophy (SMA); one-time intravenous treatment with potential lifetime benefit.
  • Xiidra (Lifitegrast) LFA-1 antagonist for treatment of dry eye disease; addresses ocular inflammation.
  • Tafinlar (Dabrafenib) + Mekinist (Trametinib) BRAF/MEK inhibitor combination for BRAF V600 mutation-positive melanoma, NSCLC, and pediatric low-grade glioma.
  • Piqray (Alpelisib) PI3K inhibitor for PIK3CA-mutated breast cancer; first targeted therapy for PIK3CA mutation.
  • Sandoz Antibiotics Portfolio Sandoz generic antibiotics including cephalosporins; essential medicines for infectious disease treatment.

Companies that use Novartis China

Customer profile

Ideal customer profiles2 records

Novartis China technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Novartis China partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights6 records

Novartis China competitors and assessment

Company assessment

Direct peers

  • Roche China: Roche China is the China subsidiary of F. Hoffmann-La Roche, a direct multinational peer with overlapping oncology, ophthalmology, and immunology portfolios, including breast cancer and ophthalmology assets that compete directly with Novartis's Kisqali and Beovu.
  • Eli Lilly China: Eli Lilly China competes with Novartis in oncology, immunology, and diabetes/obesity (cardiometabolic), with overlapping self-injection and self-administration platforms and similar NRDL negotiation dynamics.
  • Sanofi China: Sanofi China is a direct peer in immunology, rare disease, and specialty care, operating comparable hospital sales, patient support, and NRDL inclusion processes for high-cost innovative biologics.
  • Bristol-Myers Squibb China: Bristol-Myers Squibb China directly competes with Novartis in oncology (immuno-oncology vs. Kisqali/Tabrecta) and operates a similar NRDL-driven access model for innovative specialty drugs in mainland China.
  • AstraZeneca China: AstraZeneca China is a leading multinational oncology and rare disease franchise with strong NRDL inclusion rates, competing with Novartis in lung cancer (Tabrecta), breast cancer, and specialty cardiovascular therapy.
  • AbbVie China: AbbVie China directly competes with Novartis's immunology franchise (Cosentyx vs. Humira/Skyrizi/Rinvoq) and operates similar specialty biologic reimbursement and NRDL access strategy in mainland China.
  • Merck & Co. (MSD) China: MSD China competes directly with Novartis in oncology (Keytruda versus Kisqali/Tabrecta) and runs a parallel NRDL negotiation and hospital sales infrastructure, making it a near-comparable multinational peer in oncology access strategy.
  • GSK China: GSK China competes in specialty pharmaceuticals and vaccines in China with parallel hospital sales models and NRDL negotiation dynamics, making it a relevant multinational peer for portfolio and channel comparison.
  • Bayer China: Bayer China competes with Novartis's cardiovascular franchise (Leqvio, Nuoxintuo) and oncology offerings, operating comparable hospital-focused sales and NRDL inclusion processes for innovative chronic disease drugs.
  • Pfizer China: Pfizer China operates a similarly diversified innovative pharmaceutical franchise across oncology, rare disease, and immunology in mainland China, making it a comparable multinational peer for portfolio breadth, hospital channel coverage, and NRDL strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Novartis China financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novartis China leadership team

Management profile

Number of profiles

Novartis China subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Novartis China funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novartis China M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis China

What does Novartis China do?

Novartis China develops, manufactures, and commercializes innovative pharmaceutical medicines across multiple therapeutic areas including oncology, immunology, neuroscience, cardiovascular, ophthalmology, and rare diseases. The company operates through wholly-owned subsidiaries handling pharmaceutical manufacturing, biomedical research, and trading, distributing products via medical representatives to hospitals and healthcare institutions across mainland China.

Is Novartis China a public or private company?

Novartis China is a public company. It is classified as public and is currently operating.

When was Novartis China founded?

Novartis China was founded in 1996. It employs 251 to 500 people.

Where is Novartis China based?

Novartis China is headquartered in Beijing, China, in the Asia region.

Who are Novartis China's main competitors?

Direct peers on record are Roche China, Eli Lilly China, Sanofi China, Bristol-Myers Squibb China, AstraZeneca China, AbbVie China, Merck & Co. (MSD) China, GSK China, Bayer China and Pfizer China.

Does Novartis China have an API?

No public API is recorded for Novartis China.

What industry is Novartis China in?

Novartis China's product category is Innovative Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales